Autoimmune Hemolytic Anemia Clinical Trial
Official title:
Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
T follicular helper (TFH) cells represent a T cell subset dedicated to the activation of B cells. They have been involved in the pathogenesis of autoimmune diseases in humans such as lupus and Sjögren disease. We recently showed that TFH are implicated in the activation of autoreactive B lymphocytes during ITP. Autoimmune hemolytic anemia (AIHA) is an autoimmune disease due to antibodies targeting red blood cells. To date, the role of TFH in the pathogenesis of AIHA is not known. We hypothesize that AIHA is associated with an increase in the number and/or function of TFH, that could participate in the activation of autoreactive B lymphocytes.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05057481 -
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
|
Phase 3 | |
| Recruiting |
NCT05937828 -
OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
|
||
| Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
| Completed |
NCT03269292 -
Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
|
||
| Recruiting |
NCT05694312 -
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
|
Phase 2 | |
| Completed |
NCT03538041 -
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
|
Phase 2 | |
| Recruiting |
NCT03918265 -
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
|
Phase 4 | |
| Completed |
NCT02389231 -
Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03576742 -
Severe Immune Cytopenia Registry Www.Sic-reg.Org
|
||
| Active, not recruiting |
NCT04657094 -
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02877706 -
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
|
||
| Recruiting |
NCT05931718 -
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
|
||
| Completed |
NCT02158195 -
Immunopathology of Autoimmune Hemolytic Anemia
|
||
| Completed |
NCT00001630 -
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Phase 1 | |
| Withdrawn |
NCT04039477 -
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
|
Phase 2 | |
| Recruiting |
NCT04024202 -
Data Registry of Auto Immune Hemolytic Anemia
|
||
| Not yet recruiting |
NCT05711264 -
Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
|
||
| Completed |
NCT02689986 -
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
|
Phase 2 | |
| Recruiting |
NCT06212154 -
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
|
Phase 1 | |
| Completed |
NCT04057703 -
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
|